CNM-Au8 May Be Responsible for Slower ALS Progression Seen in Phase 2 Trial

CNM-Au8 May Be Responsible for Slower ALS Progression Seen in Phase 2 Trial

294582

CNM-Au8 May Be Responsible for Slower ALS Progression Seen in Phase 2 Trial

Participants in a placebo-controlled Phase 2 clinical trial of CNM-Au8, Clene Nanomedicine’s investigational oral therapy for amyotrophic lateral sclerosis (ALS), are showing several signs of slower disease progression than expected in the natural course of the disease, interim blinded data show. Notably, a considerable proportion of participants demonstrated improvements in the health and functioning of motor neurons — the specialized nerve cells that control voluntary movement and are gradually lost in ALS — as well…

You must be logged in to read/download the full post.